BJH - volume 11, issue Abstract Book BHS, february 2020
K. Kehoe , S. Weekx , S. Vermeiren , K. Ver Elst , T. Eyckmans MD, C. Schuermans MD, J. Lemmens MD
BJH - volume 10, issue 5, september 2019
C. Schuermans MD
At the EHA annual meeting of 2019, interesting new data with regard to myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) were presented. For patients with high-risk myelofibrosis (MF) who have failed or are intolerant to ruxolitinib (rux) as well as for patients with higher risk MDS, the prognosis is poor and treatment options are few. There is still a large unmet medical need for these patient groups and new therapies are eagerly awaited. The same holds true for patients with advanced systemic mastocytosis (AdvSM). For this patient group very promising data about a new inhibitor of KIT D816V were presented. In contrast, most chronic myeloid leukemia (CML) patients have a much brighter outlook with the currently available tyrosine kinase inhibitors (TKI) treatments and some can even stop their TKI and have a durable treatment-free remission (TFR). A short update of the DASFREE and ENESTfreedom data will be discussed below. Some CML patients however do not reach their treatment goals and are waiting for new treatment options. Also data on pregnancy outcomes in CML patients were discussed.
(BELG J HEMATOL 2019;10(5):188–94)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
M. Criel , F. Declau , C. Schuermans MD, K. Ver Elst , S. Vermeiren , S. Weekx , J. Lemmens MD
BJH - volume 4, issue 4, december 2013
T. Devos MD, PhD, N. Straetmans MD, PhD, C. Schuermans MD, S. Benghiat MD, PhD, V. Robin MD, P. Lewalle MD, PhD, P. Mineur MD, G. Verhoef MD, PhD, L. Knoops MD, PhD
Diagnostic and management guidelines for myelofibrosis patients are presented in this paper. As a consequence of the rapid evolution and progress in this domain over the last years, the need was felt by the BHS MPN subcommittee to update these guidelines for our country. The different prognostic scores in myelofibrosis, the diagnostic tools and treatment options with the focus on new possibilities are discussed.
(BELG J HEMATOL 2013;4(4): 127–137)
Read moreBJH - 2013, issue BHS Abstractbook, january 2013
J. Caers MD, PhD, M-C. Vekemans MD, I. Vande Broek MD, PhD, P.H. Mineur , K. Beel MD, PhD, V. Maertens MD, C. Schuermans MD, F. Leleu , G. Vanstraelen , H. Demuynck MD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD, G. Bries MD, PhD, A. Van de Velde MD, M. Delforge MD, PhD, C. Doyen MD, PhD
Top
